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Background. Heartburn and acid reﬂux (HB/RF) are associated with increased severity of nausea and vomiting. The ability of acid-
reducing drugs to reduce symptoms of nausea and vomiting of pregnancy has not been previously tested. Objective. To determine
whether acid-reducing pharmacotherapy decreases the severity of NVP symptoms. Methods. We studied a cohort of women
experiencing NVP, who were also experiencing HB/RF. Women were counseled to commence acid-reducing pharmacotherapy.
The eﬀectiveness of the acid-reducing medication in decreasing symptoms of both HB/RF and NVP was measured. Results. Acid-
reducing drugs resulted in signiﬁcant decreases in PUQE (9.6 ± 3.0t o6 .5 ± 2.5, P<. 0001) and well-being scores from the initial
(4.0 ± 2.0) to the follow-up interview (6.8 ± 1.6, P<. 0001). After intervention with acid-reducing pharmacotherapy, a reduction
in acid symptoms correlated signiﬁcantly with reduction in NVP (R2 = 0.72, P<. 001). Conclusion. This is the ﬁrst study to
demonstrate that management of HB/RF can reduce the severity of NVP.
Copyright © 2009 Simerpal Kaur Gill et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Nausea and vomiting of pregnancy (NVP) is the most
common medical condition in pregnancy, experienced by
up to 80% of women [1]. NVP has been shown to severely
aﬀect a woman’s quality of life and her ability to function,
especially when improperly managed [2]. Antiemetics are
usually successful in managing NVP; however, certain med-
ical conditions or symptoms, such as heartburn and/or acid
reﬂux (HB/RF), can exacerbate the severity of NVP [3].
Heartburn and/or acid reﬂux are common medical
disorders; it has been estimated that the incidence of gastroe-
sophageal reﬂux disorders in pregnancy ranges between 40%
and 85% [4, 5]. Symptoms associated with gastroesophageal
reﬂux disorders or dyspepsia may include heartburn, acid
reﬂux, regurgitation, eructation, ﬂatulence, stomach bloat-
ing, indigestion, and sensation of a lump in the throat and
may even aﬀect quality of sleep [6, 7]. These aforementioned
symptoms can occur any time during pregnancy, and
the severity of symptoms ranges possibly as a result of
gastrointestinal tract motility changes due to increased levels
of circulating sex hormones [8]. Similar changes in gastric
motility and dysrhythmias have been observed in women
suﬀering from NVP [8].
In a recent prospective, cohort study, we demonstrated
that women experiencing both NVP and heartburn and/or
acid reﬂux (n = 194) experienced greater severity of NVP
compared to women who did not have any heartburn
and/or acid reﬂux (N = 188) after controlling for certain
confounders [9]. Trends were observed with more women
experiencing both heartburn and acid reﬂux classifying their
NVP as severe compared to controls and compared to
womenonlyexperiencingeitherheartburnoracidreﬂux[9].
However, presently no study has examined the eﬀectiveness
of acid-reducing pharmacotherapy on NVP symptoms.
The objective of this study was to quantify whether
acid-reducing pharmacotherapy is eﬀective in decreasing the
severity of NVP in women experiencing HB/RF.
2. Methods
The Motherisk Program, located at the Hospital for Sick
Children in Toronto, has a specialized helpline for the2 Obstetrics and Gynecology International
Table 1: Motherisk-pregnancy-unique quantiﬁcation of emesis and nausea (PUQE) scoring system. The PUQE scale is a validated scoring
system to quantify the severity of NVP based on quantiﬁcation of the 3 physical symptoms of NVP (nausea, vomiting, and retching) [11].
How many hours in past 24 hours had
you felt nauseated/sick to stomach?
None (1) 1 hour or less (2) 2-3 hours (3) 4–6 hours (4) >6h o u r s( 5 )
How many times in the past 24 hours
did you vomit?
≥7 times (5) 5-6 times (4) 3-4 times (3) 1-2 times (2) None (1)
How many times in the past 24 hours
did you experience gagging or
retching or dry heaves?
None (1) 1-2 times (2) 3-4 times (3) 5-6 times (4) ≥7 times (5)
management of NVP. Women from Canada and the US
experiencing NVP can call a toll-free service (1-800-436-
8477) to receive pharmacological and nonpharmacological
advice on the management of NVP. This evidence-based
counseling is based on research and continuous systematic
review of emerging clinical and experimental evidence [10].
For the purpose of the present study, we enrolled women
counseled by the NVP Helpline from November, 2007 to
June, 2008. The study group consisted of all women who
experienced heartburn and/or acid reﬂux while suﬀering
from NVP. As per our standard, evidence-based counseling
[10], these women were advised by us to commence on acid-
reducingpharmacotherapy,andbasedontheseverityoftheir
HB/RF symptoms and on previous pregnancy use, if any,
antacids, histamine 2 blockers, or proton pump inhibitors
were recommended. Additionally, as histamine 2 blockers
are available over-the-counter in Canada, usually they are
recommended initially. All women agreed to continue their
antiemetic at the dose taken prior to adding the acid-
reducing medication. Women who changed their antiemetic
dose were excluded from analysis.
A standard interview was conducted, where detailed
quantiﬁcationofsymptomswasobtainedusingthefollowing
validated tools: (1) the Pregnancy-Unique Quantiﬁcation of
Emesisandnausea(PUQE)score[11](Table 1);(2)thewell-
being score [12] ranging from 0–10 was recorded based on
how the woman felt overall compared to how she felt before
pregnancy; (3) a self-report of how the woman perceived her
symptoms(mild,moderate,severe).Inaddition,werecorded
the time of onset of the NVP symptoms, gravidity, maternal
age at conception, gestational age at the initial interview,
and at follow-up, medical conditions that are associated with
increased severity of NVP, medication use and the severity of
NVP in previous pregnancies.
A standard follow-up interview was subsequently con-
ducted to determine PUQE and Well-being scores and to
inquire as to the acid-reducing pharmacotherapy used. To
determine the role of acid-reducing pharmacotherapy in
decreasing the severity of NVP, women were asked to rate
on a scale of 0–10, the eﬀectiveness of their medication in
reducing their acid symptoms, and the eﬀectiveness of this
medication in reducing their NVP.
Paired t-test was used to compare the mean PUQE
and Well-being scores between the initial and follow-up
interviews. Linear regression was used to determine the rela-
tionship between the reduction in heartburn and acid reﬂux
and NVP. Similarly, linear regression was also performed on
the initial PUQE scores and the change in PUQE scores, and
on the onset of NVP and the onset of symptoms of HB/RF.
Statistical analyses were conducted with the SigmaStat
program version 3.1 (Systat Software Inc., 2000, Ill, USA).
3. Results
Of 140 women, there were 80 women who experienced
HB/RF but were not stabilized on antiemetics and therefore
were excluded from our analysis. The ﬁnal cohort consisted
of 60 women with NVP: 14 experienced only heartburn,
35 experienced only acid reﬂux, and 11 reported on both
heartburn and acid reﬂux. Of the women included in our
analysis, the self-reported severity of NVP was as follows:
72% of women classiﬁed their NVP as severe, 19% as
moderate, and 9% as mild.
Mean gestational ages at initial counseling and at follow-
up were 9.6 ± 3.8w e e k sa n d1 2 .4 ± 2.1 weeks, respectively.
Mean gestational age at onsets of NVP was at 5.5 ± 3.0
weeks, and mean gestational age at which symptoms of
HB/RF occurred was 6.8 ± 2.4 weeks. Additionally, linear
regression demonstrated that the onsets of NVP and HB/RF
were signiﬁcantly correlated (R2 = 0.25, P = .004).
There were no signiﬁcant diﬀerences in PUQE scores of
women excluded from the study and initial PUQE scores
of women included in the study (9.5 ± 2.5a n d9 .6 ± 3.0,
P = .2376). Use of acid-reducing medication resulted in
a signiﬁcant decrease in PUQE scores at follow-up (from
9.6 ± 3.0t o6 .5 ± 2.5, P<. 0001, Figure 1). Similarly, there
was a signiﬁcant improvement in the Well-being scores from
the initial (4.0 ± 2.0) to the follow-up interview (6.8 ± 1.6,
P<. 0001, Figure 2).
The most commonly used acid-reducing pharmacother-
apy was histamine-2 blockers, used by two-thirds of women
(40/60). Proton pump inhibitors were used by 13 out
of 60 women, and other over-the-counter antacids were
used by 7 out of 60 women. The mean eﬀectiveness of
acid-reducing pharmacotherapy rated by the women was
8.2 out of 10, and the mean eﬀectiveness of the acid-
reducing pharmacotherapy in reducing NVP was 7.7 out
of 10. Women noticed improvement, on average, 3-4 days
after commencing acid-reducing pharmacotherapy. Linear
regression demonstrated that a reduction in acid symptoms
signiﬁcantly predicted the reduction in NVP with the
use of acid-reducing pharmacotherapy (R2 = 0.72,P<
.001, Figure 3). As the severity of PUQE increased, there
was a greater reduction in PUQE scores after the use ofObstetrics and Gynecology International 3
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Figure 1: PUQE scores of women experiencing HB/RF and NVP
at initial call and at follow-up after the use of acid-reducing
pharmacotherapy; Final (marked “∗”): P<. 0001, compared to
control.
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Figure 2: Well-being scores of women experiencing HB/RF and
NVP at initial call and at follow-up after the use of acid-reducing
pharmacotherapy; Final (marked “∗”): P<. 0001, compared to
control.
acid-reducing pharmacotherapy as demonstrated by linear
regression (R2 = 0.15,P = .003).
4. Discussion
Our data demonstrate for the ﬁrst time that acid-reducing
pharmacotherapy reduces the severity of NVP. There was a
strong correlation between the reduction in acid symptoms
and the reduction in the severity of NVP suggesting that
treatment of HB/RF will cause improvement in NVP.
Women reported an improvement in both HB/RF and NVP
symptoms within 3 to 4 days after starting acid-reducing
pharmacotherapy. Furthermore, women experiencing the
most severe NVP had the greatest change in their NVP after
using acid-reducing pharmacotherapy. These results support
our initial observational study [9] in suggesting that HB/RF
is a signiﬁcant contributor to NVP. Additionally, the onset of
symptoms of NVP signiﬁcantly correlated with the onset of
symptoms of HB/RF providing further evidence that HB/RF
exacerbates NVP.
Since withholding treatment was not considered ethical
in the context of our clinical practice in the NVP healthline,
our study could not recruit a cohort of women experiencing
symptoms of HB/RF who did not use acid-reducing phar-
macotherapy. The lack of a comparison group is a limitation;
however, the results from this pilot study provide valuable
data for a future controlled study. To ensure, however,
that the potential eﬀect of acid-reducing drugs on NVP
severity can be attributed to these medications, we excluded
women who increased their antiemetics during the study.
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Figure 3: Linear regression comparing the eﬀectiveness of acid-
reducing pharmacotherapy in reducing HB/RF, and in reducing
NVP. Women rated eﬀectiveness from zero (no eﬀect) to 10
(maximal eﬀect); R2 = 0.72,P<. 001.
This exclusion was done prior to evaluating the potential
eﬀects of acid suppressing drugs on the severity of NVP.
Nausea and vomiting of pregnancy and HB/RF result in
adverse maternal outcomes including decreasing a woman’s
quality of life and her ability to function [1, 2], and more
serious gastrointestinal morbidities such as gastroesophageal
reﬂux disorder or peptic ulcers [13]. Treatment of HB/RF
by histamine 2 blockers or proton pump inhibitors should
be considered to alleviate symptoms, especially since these
c l a s s e so fd r u g sh a v eb e e nq u i t ew e l ls t u d i e di np r e g n a n c y ,
and have not been associated with increased fetal risks [14–
28].
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